← Leaderboards
Xiang Ling
Canget Biotekpharma, Llc
$1,475,644
Attributed
$2,951,288
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $988.3K · FY2014–23$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,951,288 · 3
By mechanism
R44$2,326,369 · 1
R43$624,919 · 2
Top collaborators
- Fengzhi Li6 shared
Others in their field
Top investigators on “Survivin”
- Dario C. Altieri · Wistar Institute$15,749,150
- Maciej S Lesniak · Northwestern University$9,074,165
- Gary A Piazza · Southern Research Institute$6,260,773
- Mien-Chie Hung · University Of Texas Md Anderson Can Ctr$5,939,819
- Vladimir P Torchilin · Northeastern University$5,532,741
- Michael G Brattain · University Of Texas Hlth Sci Ctr San Ant$5,273,572
Research focus
SurvivinAnimal ModelBirc4 GeneTumorSmall Business Innovation Research GrantClinical TrialsToxic EffectPharmaceutical PreparationsProteinsAbcg2 GeneDrug KineticsClinical ResearchColonResponseSmall MoleculePlayColon CarcinomaMalignant NeoplasmsCancer CellFightingInvestigational DrugsPlasmaDoseCessation Of Life
Grant awards (6)
Perform non-GLP and GLP TOX/TK studies, and file a novel drug IND with the FDA for advanced pancreatic cancer patient clinical trials$400,000
R43 · FY2023 · CA · contact PI
A novel small molecule FL7N-1 for treating pediatric cancer retinoblastoma$224,919
R43 · FY2018 · CA · contact PI
A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer$210,000
R44 · FY2018 · CA · contact PI
A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer$988,326
R44 · FY2016 · CA · contact PI
A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer$903,055
R44 · FY2015 · CA · contact PI
A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer$224,988
R44 · FY2014 · CA · contact PI